Literature DB >> 8955356

Localisation of the C1q binding site within C1q receptor/calreticulin.

G R Stuart1, N J Lynch, J Lu, A Geick, B E Moffatt, R B Sim, W J Schwaeble.   

Abstract

C1q receptor (C1qR/collectin receptor) is located on many cell types. Binding of C1q to these cells elicits numerous responses. Protein sequencing has shown that C1qR is almost identical to calreticulin (CaR), an abundant multifunctional protein. Radioiodinated C1qR and CaR bind to C1q with identical characteristics. Three recombinant C1qR/CaR domains (N-, C-terminal domains and central P-domain) were expressed using the Thiofusion system, and used to study the interaction with C1q. Both the N- and P-domains were implicated in C1q binding. A region, termed the S-domain, spanning the N and P intersection was expressed, and showed concentration-dependent binding to C1q, demonstrating that the C1q binding site lies within this region.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8955356     DOI: 10.1016/s0014-5793(96)01156-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  15 in total

Review 1.  C1q receptors.

Authors:  P Eggleton; A J Tenner; K B Reid
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

2.  Anti-C1q receptor/calreticulin autoantibodies in patients with systemic lupus erythematosus (SLE).

Authors:  R H van den Berg; C E Siegert; M C Faber-Krol; T W Huizinga; L A van Es; M R Daha
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

3.  Amblyomma americanum tick calreticulin binds C1q but does not inhibit activation of the classical complement cascade.

Authors:  Tae Kwon Kim; Adriana Mércia Guaratini Ibelli; Albert Mulenga
Journal:  Ticks Tick Borne Dis       Date:  2015-02       Impact factor: 3.744

4.  A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.

Authors:  Emilian Racila; Brian K Link; Wen-Kai Weng; Thomas E Witzig; Stephen Ansell; Matthew J Maurer; Jian Huang; Christopher Dahle; Ahmad Halwani; Ronald Levy; George J Weiner
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

Review 5.  Subversion of complement by hematophagous parasites.

Authors:  Hélène Schroeder; Patrick J Skelly; Peter F Zipfel; Bertrand Losson; Alain Vanderplasschen
Journal:  Dev Comp Immunol       Date:  2009       Impact factor: 3.636

6.  C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition.

Authors:  Helena Païdassi; Pascale Tacnet-Delorme; Virginie Garlatti; Claudine Darnault; Berhane Ghebrehiwet; Christine Gaboriaud; Gérard J Arlaud; Philippe Frachet
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

7.  Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP.

Authors:  Xuan Jin; Huirong Ding; Ning Ding; Zhiying Fu; Yuqin Song; Jun Zhu
Journal:  J Hematol Oncol       Date:  2012-08-16       Impact factor: 17.388

8.  C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells.

Authors:  C A Ogden; A deCathelineau; P R Hoffmann; D Bratton; B Ghebrehiwet; V A Fadok; P M Henson
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

9.  Human survivin and Trypanosoma cruzi calreticulin act in synergy against a murine melanoma in vivo.

Authors:  Lorena Aguilar-Guzmán; Lorena Lobos-González; Carlos Rosas; Gerardo Vallejos; Cristián Falcón; Eduardo Sosoniuk; Francisca Coddou; Lisette Leyton; David Lemus; Andrew F G Quest; Arturo Ferreira
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

10.  In silico and in vitro studies on the protein-protein interactions between Brugia malayi immunomodulatory protein calreticulin and human C1q.

Authors:  Sunita Yadav; Smita Gupta; Chandrabose Selvaraj; Pawan Kumar Doharey; Anita Verma; Sanjeev Kumar Singh; Jitendra Kumar Saxena
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.